Biomarker test developer

Who We Are

About Biovica

Biovica: Committed to developing and commercializing novel blood-based biomarker assays.

Biovica is a Swedish biotech company founded in 2009 with a vision to improve monitoring and predicting the efficacy of cancer therapies. Our initial focus is breast cancer, a disease responsible for over 685,000 deaths a year (BCRF, 2022). We work with leading cancer institutes, collaborative groups, and pharmaceutical companies on product development with the aim of improving outcomes and lowering costs.

Clinical validation: The DiviTum^® TKa test was selected for support and funding by the European Commission Horizon 2020 phase 2 program.

Our Vision

Improved care for cancer patients

Our Mission

To transform management of cancer care through innovative biomarker-based tests

Our Values

Collaboration
We work as a team, supporting each other to create success.

Innovation
We use technology to create innovative and sustainable solutions to fulfill our mission.

Appreciation
We act ethically and responsibly to build trust.

What oncologists say

These results should serve as the basis for future clinical studies to distinguish patients with estrogen receptor metastatic breast cancer who might be best treated with endocrine therapy alone.

Professor Daniel Hayes MD

University of Michigan Rogel Cancer Center

Our results imply that DiviTum®TKa is prognostic both at baseline and on treatment with CDK4/6 inhibitors.

Cynthia Ma, MD, PhD

Professor of Medicine and medical oncologist Division of Medical Oncology, Washington University, St. Louis.

These results are highly encouraging and highlight the potential of DiviTum®TKa to evaluate treatment efficacy already during the first weeks of therapy, and afterwards to monitor the disease.

Dr. Luca Malorni

Principal Investigator of the Study at Prato Hospital, Italy

The results from our study support using DiviTum® TKa to monitor efficacy during treatment and predict response to palbociclib, a standard therapy for women with metastatic breast cancer.

Dr. Jairam Krishnamurthy

Principal Investigator of the Study at Division of Oncology/Hematology, University of Nebraska Medical Center

Read full testimonials

>4,500

Numbers of patients in studies

Publications

Pharma Projects

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_C4JTGTKQB3	2 years	This cookie is installed by Google Analytics.
_gat_UA-108462189-1	1 minute	A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress	30 minutes	Hotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen	30 minutes	Hotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample	2 minutes	Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample	2 minutes	Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.

Cookie	Duration	Description
_hjSession_2792140	30 minutes	No description
_hjSessionUser_2792140	1 year	No description